Copyright
©The Author(s) 2022.
World J Clin Pediatr. Jul 9, 2022; 11(4): 360-368
Published online Jul 9, 2022. doi: 10.5409/wjcp.v11.i4.360
Published online Jul 9, 2022. doi: 10.5409/wjcp.v11.i4.360
Table 1 Clinical and laboratory features of the study population
Study group (n = 20) | Controls (n = 20) | |
Male:female ratio | 1.5:1 | 1.5:1 |
Age at diagnosis < 5 yr | 9 | - |
Age at diagnosis >5 yr | 11 | - |
Mean age at enrolment (yr) | 10.1 | 9.1 |
Mean duration of follow-up (yr) | 5.5 | - |
Treatment received during the acute phase | - | |
IVIg (mg/dL) | 20 | |
Aspirin (mg/dL) | 20 | |
CAAs (mg/dL) | 4/20 | - |
Lipid profile | mean ± SD | - |
LDL (mg/dL) | 74.73 ± 27.82 | |
TG (mg/dL) | 118.72 ± 104.32 | |
VLDL (mg/dL) | 16.96 ± 6.72 | |
HDL (mg/dL) | 44.93 ± 11.40 | |
TC (mg/dL) | 139.76 ± 27.16 | |
Body mass index (kg/m2) | 16.68 ± 3.25 | - |
Lipid profile (18/20) | - | |
High TC (mg/dL) | 2 | |
High LDL (mg/dL) | 2 | |
Low HDL (mg/dL) | 6 | |
Borderline HDL (mg/dL) | 11 | |
High TG (mg/dL) | 4 | |
High VLDL (mg/dL) | 0 |
Table 2 Adipocytokine profile in patients with Kawasaki disease and healthy controls
Study group (n = 20), Median (IQR) | Controls (n = 20), Median (IQR) | P value | |
Adiponectin (µg/mL) | 12.20 (9.76, 17.97) | 13.95 (11.17, 22.58) | 0.18 |
Leptin (ng/mL) | 1.83 (1.13, 3.80) | 1.10 (0.41, 2.88) | 0.09 |
Resistin (ng/mL) | 27.77 (18.66, 48.90) | 21.20 (14.80, 27.00) | 0.04a |
Table 3 Correlation of adipocytokines with different lipoproteins, body mass index and age of the patients with Kawasaki disease
Characteristics | Leptin | Adiponectin | Resistin | |||
Correlation coefficient | P value | Correlation coefficient | P value | Correlation coefficient | P value | |
LDL (mg/dL) | 0.030 | 0.90 | -0.223 | 0.34 | -0.003 | 0.99 |
TG (mg/dL) | 0.076 | 0.75 | -0.018 | 0.94 | 0.169 | 0.47 |
VLDL (mg/dL) | -0.076 | 0.75 | 0.330 | 0.15 | 0.105 | 0.65 |
HDL (mg/dL) | -0.037 | 0.87 | 0.505 | 0.47 | 0.470 | 0.03a |
Total cholesterol (mg/dL) | 0.033 | 0.89 | -0.379 | 0.09 | -0.217 | 0.35 |
BMI (kg/m2) | 0.574 | 0.02a | -0.334 | 0.20 | -0.280 | 0.29 |
Age (yr) | 0.379 | 0.09 | -0.057 | 0.81 | -0.128 | 0.59 |
Table 4 Comparison of published literature on circulating adipocytokines in children with Kawasaki disease
Ref. | Number of cases/controls | Stage of disease | CAA | Resistin | Leptin | Adiponectin |
Takeshita et al[30], 2006 | Cases-20; Febrile controls-15; Healthy controls-15 | Acute phase (day 4-6); Convalescent phase (day 25-39) | NA | - | - | Adiponectin levels were significantly reduced in the acute phase compared to the convalescent phase. No difference between the convalescent phase and controls. |
Nozue et al[15], 2010 | Cases-44; Controls-17 | Acute | 0 | Increased during the acute phase and returned to normal after IVIg administration | Not assessed | Not assessed |
Fukunaga et al[19], 2010 | Acute phase KD-9; Convalescent phase KD-20; Controls-21 | Both acute and convalescent (> 2 yr from KD onset); 6.72 ± 3.2 yr following KD (for convalescent cases) | NA | Not assessed | Not assessed | Total and HMW adiponectin levels were lower in acute KD compared to controls; MMW and LMW adiponectin levels decreased in convalescent cases compared to controls |
Qi et al[31], 2012 | Cases-40; Controls-15 | Acute; Afebrile; Subacute phase | 6 | Significantly high in the acute stage of KD and decreased with the course of the disease; No difference between patients with KD in the afebrile and subacute phase compared with the controls | ||
Liu et al[16], 2012 | KD-80; Controls-85 | Acute | 39 | Increased compared to controls. No difference between KD with and without CAAs | No difference | Increased compared to controls. No difference between KD with and without CAAs |
Kemmotsu et al[17], 2012 | Cases-56; Healthy controls-30; Febrile controls-31 | Acute | 4 | Markedly elevated in acute stage and returned to normal after IVIg administration. Non-responders to IVIg had very high resistin levels | No difference | No difference |
Kim et al[18], 2014 | Cases-40; Febrile controls-32; Healthy controls-15 | Acute | 12 | Markedly elevated in the acute stage but did not predict development of CAAs | Not assessed | Not assessed |
Zhang et al[32], 2018 | Cases-80; Febrile controls-20; Healthy controls-20 | Acute phase | 24 | Decreased compared to febrile controls. However, no difference compared with healthy controls | ||
Zhang et al[33], 2021 | Cases-42; Controls-20 | Acute phase (1-10 d); Subacute phase (11-20 d); Convalescent phase (21-30 d) | 18 | Serum adiponectin was significantly lower compared to controls | ||
Present study, 2021 | KD convalescent phase-20; Controls-20 | Convalescent; > 3 yr of follow-up; (mean 5.5 yr) | 4 | Elevated in patients with KD compared to controls | Trend towards higher levels of leptin in patients with KD compared to controls | No difference |
- Citation: Praharaj DL, Rawat A, Gupta A, Arora K, Pilania RK, Bhattad S, Singh S. Adipocytokine profile in children with Kawasaki disease at a mean follow-up period of 5.5 years: A study from North India. World J Clin Pediatr 2022; 11(4): 360-368
- URL: https://www.wjgnet.com/2219-2808/full/v11/i4/360.htm
- DOI: https://dx.doi.org/10.5409/wjcp.v11.i4.360